Kodiak Sciences Announces Positive Phase 3 GLOW2 Results for Zenkuda in Diabetic Retinopathy, Accelerating BLA Submission
KOD has more than doubled off its 52-week low of $1.92 on elevated volume (14× avg).
Summary
Kodiak Sciences announced positive Phase 3 results for Zenkuda in diabetic retinopathy, showing superiority over sham and leading to an accelerated BLA submission timeline.
Key Events · Product Development and Regulatory · KOD
-
Positive Phase 3 GLOW2 Results
Zenkuda (tarcocimab tedromer) demonstrated superiority over sham in the GLOW2 Phase 3 study for diabetic retinopathy.
-
Significant Efficacy Achieved
62.5% of Zenkuda-treated patients achieved a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001).
-
Reduced Sight-Threatening Complications
Zenkuda reduced the risk of developing sight-threatening complications by 85% compared to sham.
-
Favorable Safety Profile
The drug was well-tolerated with a 0% intraocular inflammation rate and low cataract adverse event rates.
Analysis · KOD · Life Sciences
Kodiak Sciences reported highly positive topline results from its GLOW2 Phase 3 study for Zenkuda (tarcocimab tedromer) in diabetic retinopathy. The study demonstrated Zenkuda's superiority over sham with strong statistical significance in improving diabetic retinopathy severity and reducing sight-threatening complications. This successful outcome, coupled with a favorable safety profile, provides Zenkuda with a multi-indication BLA-ready profile, prompting the company to accelerate its Biologics License Application submission plans. This is a critical de-risking event for Kodiak, validating its proprietary ABC Platform and significantly advancing its lead product candidate towards commercialization, which could be a major catalyst for future revenue growth.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KOD was trading at $39.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $1.92 to $40.46. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.